Annual report pursuant to Section 13 and 15(d)

OPERATING BUSINESS SEGMENT AND INTERNATIONAL OPERATION INFORMATION (Tables)

v3.22.0.1
OPERATING BUSINESS SEGMENT AND INTERNATIONAL OPERATION INFORMATION (Tables)
12 Months Ended
Dec. 31, 2021
Segment Reporting [Abstract]  
Schedule of reportable business segment information
Reportable business segment information for the years ended December 31, 2021 and 2020 is as follows (dollar amounts in thousands):
Year Ended December 31, 2021 2020
Net sales:    
Asia $ 176,860  $ 138,717 
Europe 91,539  77,688 
North America 149,746  145,481 
Latin America and Other 25,939  23,319 
Total net sales 444,084  385,205 
Contribution margin (1):    
Asia 89,939  66,801 
Europe 30,959  26,014 
North America 56,922  50,193 
Latin America and Other 10,953  9,771 
Total contribution margin 188,773  152,779 
Selling, general and administrative (2) 154,103  131,297 
Operating income 34,670  21,482 
Other income (loss), net (2,848) 1,339 
Income before provision for income taxes $ 31,822  $ 22,821 
___________________________
(1) Contribution margin consists of net sales less cost of sales and volume incentives expense.
(2)  Service fees in China totaled $18.7 million and $11.7 million for the years ended December 31, 2021 and 2020, respectively. These service fees are included in our selling, general and administrative expenses.
Year Ended December 31, 2021 2020
Capital expenditures:    
Asia $ 1,081  $ 542 
Europe 142  34 
North America 5,371  4,267 
Latin America and Other 72  62 
Total capital expenditures $ 6,666  $ 4,905 
Depreciation and amortization:    
Asia $ 1,825  $ 1,919 
Europe 64  77 
North America 9,206  8,673 
Latin America and Other 67  74 
Total depreciation and amortization $ 11,162  $ 10,743 

As of December 31, 2021 2020
Assets:    
Asia $ 104,659  $ 82,572 
Europe 15,486  16,398 
North America 131,207  142,324 
Latin America and Other 7,522  8,204 
Total assets $ 258,874  $ 249,498 
Schedule of consolidated net sales revenue by geographical locations From an individual country perspective, only the United States and South Korea comprise approximately 10 percent or more of consolidated net sales for the years ended December 31, 2021 and 2020 as follows (dollar amounts in thousands):
Year Ended December 31, 2021 2020
Net sales:    
United States $ 138,174  $ 134,976 
South Korea 61,107  62,041 
Other 244,803  188,188 
Total net sales $ 444,084  $ 385,205 
Schedule of revenue generated by each of the Company's product lines Revenue generated by each of our product lines is set forth below (dollars in thousands):
Year Ended December 31, 2021 2020
Asia:    
General health $ 50,044  $ 36,445 
Immunity 1,599  847 
Cardiovascular 48,019  40,496 
Digestive 36,069  32,605 
Personal care 17,765  10,606 
Weight management 23,364  17,718 
  176,860  138,717 
Europe:    
General health $ 40,045  $ 32,822 
Immunity 8,957  8,231 
Cardiovascular 11,787  10,863 
Digestive 23,142  18,673 
Personal care 5,149  4,663 
Weight management 2,459  2,436 
  91,539  77,688 
North America:    
General health $ 65,379  $ 61,897 
Immunity 19,563  23,036 
Cardiovascular 16,219  15,852 
Digestive 37,130  32,851 
Personal care 7,579  7,587 
Weight management 3,876  4,258 
  149,746  145,481 
Latin America and Other:    
General health $ 7,532  $ 6,867 
Immunity 2,667  3,122 
Cardiovascular 2,001  1,512 
Digestive 10,291  9,863 
Personal care 2,573  1,203 
Weight management 875  752 
  25,939  23,319 
Total net sales $ 444,084  $ 385,205 
Schedule of consolidated property, plant and equipment by geographical locations From an individual country perspective, only the United States comprise 10 percent or more of consolidated property, plant and equipment as follows (dollar amounts in thousands):
As of December 31  2021 2020
Property, plant and equipment, net    
United States $ 46,595  $ 50,025 
Other 4,262  4,330 
Total property, plant and equipment $ 50,857  $ 54,355